Q&A: How a highly clinically translatable NASH model helps new drug discovery
The industry restores confidence in NASH new drug R&D with Madrigal Pharmaceuticals’ submission of a rolling review for Resmetirom in this July and the rise of GLP-1 receptor agonists treatments for NAFLD/NASH, e.g., Semaglutide for NASH at Phase III from Novo Nordisk; Tirzepatide for NASH at Phase II from Eli Lilly; Efinopegdutide for NAFLD at Phase 2a from MSD, etc.